Skip to main content
Sign In
 

Clinical Trials

Volunteer to Be Part of a Research Study


Search

You can search for specific diseases or conditions in our Clinical Trials list (the page takes about a minute to load due to the quantity of trials).

Page through all School of Medicine clinical and research trials below, or click here to look for specific types of trials.
(It will take a few seconds to load) There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 102.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 102.
Participants with Chronic Kidney Disease and Vitamin D Deficiency Needed for a Research Study
This study will examine whether nutritional or active vitamin D supplementation will improve blood vessel function​.
Person 18-80 with chronic kidney disease stage 3B or 4 (estimated GFR 44-15 m;/min) with a vitamin D deficiency or insufficiency.  Women must not be pregnant or breastfeeding.
9/18/2014
Trouble Sleeping?
Study the effects of two different study drugs, one or two non-drug interventions and/or a combination of both to treat insomnia.
Persons 21+ who have trouble falling or staying asleep at night.
9/18/2014
MS Volunteers Needed for Research Study
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo.
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
9/18/2014
Give Us a Hand
To better understand Multiple Sclerosis in children and teens.
Between the ages of 3-20 AND have Multiple Sclerosis diagnosed before 18 OR Do not have MS
9/18/2014
Are you an African American with asthma?
 We are studying why some African American people have trouble with their asthma despite taking asthma medications.
 Children age 5-17 and non-smoking Adults age18 and older who have asthma symptoms despite asthma treatment • African American ancestry (have at least one    African American grandparent)
9/18/2014
Peanut and Tree-Nut Allergy Research Study
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction.
6-75 years of age. Have a diagnosis of peanut and/or tree-nut allergy made by either skin test or blood tests. Have no known peanut and/or tree-nut allergy.
9/18/2014
Research about the Effect of Carbamazepine medication on the Etonogestrel Contraceptive Implant (Implanon®/Nexplanon®)
Do you currently have a birth control implant (Implanon®/ Nexplanon®) and are interested in participating in a research study to better understand the effects of certain medication on the implant?
• Women ages 18-45 who have had a birth control implant 1 to 3 years • Do not take any medications that are known to effect liver enzymes • Be willing to abstain during the study period or use a secondary form of non-hormonal contraception • Have a body mass index between 15 and 30 • Have baseline systolic blood pressure
9/18/2014
Do you have human growth hormone (hGH) deficiency?
Primary: To demonstrate a clinical superiority of MOD-4023 over placebo in terms of decrease in Fat Mass (FM) in adult subjects with Growth Hormone Deficiency Secondary a. To determine the efficacy of MOD-4023 over placebo in other body composition variables (such as lean body mass and waist-to-hip ratio) b. To evaluate the safety and tolerability of MOD-4023 over placebo in adult subjects with GHD c. To determine the IGF-I and IGFBP-3 serum levels
Adult men and women aged 23 to 70 years of age diagnosed with either adult or childhood onset growth hormone deficiency (GHD).
9/18/2014
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
The purpose of this study is to gain knowledge on the topic of everyday stressors that affect the lives of children with developmental disabilities, as well as their parents/caregivers
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
9/18/2014
If you child suffers from rashes or skin allergies he or she may qualify to take part in a research study.
To test seven new antigens on the child and adolescent population to add to the current standard test
Children and adolescents 6-17 diagnosed with contact dermatitis or may have contact dermatitis who are willing to wear test patches for 2 days and are available for follow-up visits
9/17/2014
Investigations in Gestational Origins of Lifetime Development: Understanding health begins before birth. Are you in your first trimester of Pregnancy?
To learn more about how your metabolism is connected to your baby's growth and development
Healthy Women ages 18-35 who are 10-14 weeks pregnant with single baby.  Norm BMI or 30-38 who are willing to complete 5 visits during pregnancy and agreeable to an infant blood draw at birth and DXA postpartum.  Delivery must be at University of Colorado Hospital.  there is an option to take part in a 1 year follow-up which entails an additional 4 visits and another DXA at 1 year of life.
9/17/2014
We are Currently Enrolling People with Down syndrome for a study in Dr. Pelak's Brain and Vision Research lab at the University of Colorado Anschutz Medical Campus.
To examine visual brain function in people with mild memory impairments to detect early signs of Alzheimer's Disease.​
Persons 19-30 who have Down Syndrome
9/17/2014
You are invited to participate in EMERALD, as research study about Metformin and Type 1 Diabetes in Adolescents
​To determine the effects of Metformin on Cardiovascular Function in Adolescents with Type 1 Diabetes.
Persons 12-21 who have Type 1 Diabetes, non-smoker and exercise no more than 3 hours a week.  You must be willing to take metformin or placebo (sugar pill) for 3 months.   Other exclusions apply, please contract study for more information
9/17/2014
Children's Hospital, department of Pediatric Neurology is conducting a research study
Evaluating the effects of a single treatment of injected BOTOX® (Botulinum Toxin Type A) for chronic migraine(s) in adolescents.
Adolescents 12-17 who have no serious medical conditions but have at least 15 headaches a month for the last 6 months. You not have any previous BOTX treatments or are not currently using any prophylactic medicine.
9/17/2014
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links between Hypoxemia and Liver Injury
To learn if obstructive sleep apnea and low oxygen levels have a role in developing Non-Alcoholic Fatty Liver Disease (NAFLD).​​​
Children 10-17 who have a normal weight and no serious medical problems
9/17/2014
Are you using Implanon or Nexplanon for birth control?
Study on a potential treatment for bothersome bleeding/spotting related to the etonogestrel implant.
Women 18-44 who are experiencing bothersome bleeding/spotting while using Implanon or Nexplanon
9/17/2014
Exercise and Cancer Prevention Research Study
The goal of this study is to better understand the biological mechanisms associated with exercise and reduced risk for breast cancer.
You must be a female between the ages of 30-45 to participate in this study. You must be planning to live in the Denver metropolitan area for the next 10 consecutive months. You should not be a regular exerciser because this study is for people who do not exercise right now; however, you should be willing to participate in an exercise program 4 times per week for 16-weeks.
9/17/2014
Are you interested in a supervised exercise intervention?
Volunteers are needed for a research study to examine the effects of exercise on food intake and appetite regulation.
- 21-45 years old - Non- smoker - Non- Diabetic - Exercise no more than 1 time a week - Maintained your current weight for last 6 months - Have a body mass index (BMI) of 27-35 (check it out at http://nhlbisupport.com/bmi/)
9/17/2014
Study of Mood Disorder in Preschool Children
We are doing a research study to better understand what mood disorders look like in preschool children.
We are looking for volunteers who:   *    Are parents of children between the ages of 4 and 6 years 0 months.  *    Are in one of three groups:         1) Their child has no major mental health problems, and there is            no family history of major mood or psychotic disorders.          2) Their child has been diagnosed with a mood disorder, bipolar disorder, or              mood dysregulation disorder.  3) Their child has been diagnosed with attention deficit hyperactivity  disorder (ADHD).  Parents or guardians will be asked to:                *    Read and sign a consent form               *    Participate in interviews about their children. The  children will be asked to:    *    Participate in a story game    *    Take tests of verbal and nonverbal abilities   How much time will this take? The visit for the child will last from 1 to 2 hours.  The visit for the parents will last 3 to 5 hours.
9/17/2014
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
-A relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years OR -A healthy individual 18-55 years old without Multiple Sclerosis or other neurological conditions
9/17/2014
Understanding how Tysabri and Gilenya Influence the Quality of your Daily Life with Multiple Sclerosis
The purpose of this research study is to compare two medications, Tysabri and Gilenya, used in the treatment of multiple sclerosis (MS), through a few self reported patient surveys. We will ask you to complete online surveys about overall health-related quality of life, disability, fatigue, cognition and productivity. We will also want to review your medical records to understand your MS history with your permission. This study will help us understand how these drugs are impacting each aspect of your daily lives.
-Between ages 16 and 65 -Scheduled to start natalizumab or fingolimod for the first time to treat your MS
9/17/2014
Brown Adipose Tissue and Estrogen (BATE Study)
To investigate whether estrogen influences the activity of brown adipose tissue.
Healthy non-smoking women 20-40 who have regular menstrual cycles and are not on hormonal contraceptives and exercise more than once per week
9/16/2014
Type 2 Diabetes and Exercise Research Study
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
9/16/2014
Is your child 6-18 years old and interested in participating in a research study?
To study the effects of polycystic kidney disease (PKD) on blood vessel function
Children 6-22 free from kidney disease and other chronic diseases
9/16/2014
Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Lipohypertrophy Study
This study is looking at evaluating Insulin Pump Infusion sites and Continuous Glucose Monitoring sites in tissue with Lipohypertrophy. We will also be looking at using the sites for a longer duration.
Lipohypertrophy site of 3 cm or greater in diameter Ages 12-45 inclusive A1C Value of < 10% Insulin pump use of at least 3 month duration Pump use with Medtronic, Animas or T-slim Willing to wear two CGM's during the 4 weeks of the study
9/16/2014
Are you trying to lose weight?
Volunteers needed for a research study about the weight loss medication Phentermine  
Healthy and between 30-45 years of age •Have a BMI between 30 and 40 (calculate your BMI at http://www.nhlbisupport.com/bmi/) •Willing to take the weight loss medication Phentermine for a period of 8 weeks (but not currently taking any approved or investigational medication for weight loss)
9/16/2014
Participants Ages 12-15 years old Needed for Research Study
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
9/16/2014
Are you stopping your birth control because you want to become pregnant?
To look at contraception rates after birth control discontinuation.
Women 18-35 who are planning to, or have recently stopped their birth control because they want to become pregnant.
9/15/2014
Healthy Postmenopausal Women needed to participate in a research study
To test whether estrogen has different effects on blood sugar early in menopause compared to many years after menopause​.​
Women 45-70 who have gone through menopause within the past 6 years or are more than 10 years past menopause, never used hormone therapy for more than 6 months and are willing to use estrogen patches for 1 week.  Must be a non-smoker and sedentary to moderately active.
9/15/2014
Type 1 Diabetes Research Study
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
9/15/2014

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System. Sponsor Protocol # 09-07. WIRB Protocol # 20131128
Pollyea, Daniel13-2064
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients. Sponsor Protocol No. CMX001-301. WIRB Protocol No. 20131501
Gutman, Jonathan13-2441
A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML). Sponsor Protocol No. M14-212. WIRB Protocol No. 20131839
Pollyea, Daniel13-2463
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer. Sponsor Protocol No. I4J-MC-HHBB(e). WIRB Protocol No. 20101374
Lewis, Karl13-2557
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab Patients with Advanced Melanoma. Sponsor Protocol No. 006. WIRB Protocol No. 20130483
Gonzalez, Rene13-2581
Phase I Study of Platinum-based Chemoradiotherapy (CRT) with Oral Rigosertib in Patients with Intermediate or High-risk Head and Neck Squamous Cell Carcinoma. Sponsor Protocol No. 09-12. WIRB Protocol No. 20132209
Jimeno, Antonio13-2591
A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment. Sponsor Protocol No. 1042-0603. WIRB Protocol No. 20131531
Strom, Laura13-2603
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies. Sponsor Protocol No. 52M51-001. WIRB Protocol No. 20121889
Gore, Lia13-2642
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886)(Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) (SELECT-1). Sponsor Protocol No. D1532C00079. WIRB Protocol No. 20131837
Oton, Ana13-2647
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA. Sponsor Protocol No. WO29074. WIRB Protocol No. 20131502
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Multicenter, Randomized, Open-Label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Advanced Multiple Myeloma. Sponsor Protocol No. ARRAY-520-216. WIRB Protocol No. 20131633
Smith, Clayton13-2932
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant. Sponsor Protocol No. C31001. WIRB Protocol No. 20132212
Diamond, Jennifer13-2999
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
GORE® HELEX® Septal Occluder/GORE® Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO). Sponsor Protocol No. HLX 06-03. WIRB Protocol No. 20080907
Kim, Michael13-3034
A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure. Sponsor Protocol No. HW004-A. WIRB Protocol No. 20131526
Cleveland, Joseph13-3039
A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults. Sponsor Protocol No. GS-US-292-0119. WIRB Protocol No. 20131690
Campbell, Thomas13-3072